SCHEMBL21834282

SCHEMBL21834282

Cc1nnc(CC(OC(N)=O)c2cc(OCC(F)(F)F)ccc2F)o1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ GRIN2B Q13224 6/20 0.34
▸ GRIN1 Q05586 5/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GPR88 Q9GZN0 2/20 0.33
▸ CYP17A1 P05093 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ BACE2 Q9Y5Z0 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ IDH1 O75874 1/20 0.32
▸ CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21834262 0.90 MAOB (0.39) CYP2C9GRIN2BGRIN1
SCHEMBL21834274 0.87 FFAR1 (0.36) GRIN2BGRIN1GPR88
SCHEMBL21834241 0.84 KDM4E (0.36) LMNAGRIN2BGRIN1ALDH1A1KDM4E
SCHEMBL23243855 0.83 NR3C2 (0.33) LMNAKMT2AGRIN2BGRIN1
SCHEMBL21834271 0.83 GRIN2B (0.38) GRIN2BGRIN1
SCHEMBL21834280 0.83 CYP17A1 (0.39) CYP2C9GRIN2BGRIN1ALDH1A1GPR88
SCHEMBL23243869 0.82 GPR88 (0.41) CYP2C9CYP1A2MEN1LMNAKMT2A
SCHEMBL23243860 0.81 NR3C2 (0.32) KMT2AGRIN2BGRIN1
SCHEMBL23243854 0.80 NR3C2 (0.32) LMNAKMT2A
SCHEMBL23243841 0.80 MAOB (0.38) CYP2C9GRIN2BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034101-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-01-30 — — US claimed
US-12145914-B2 Compound having oxadiazole and pharmaceutical composition containing the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-11-19 — — US claimed
US-20230150955-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-05-18 — — US claimed
US-11603358-B2 Compound having oxadiazole and pharmaceutical composition containing the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-03-14 — — US claimed
US-20220024886-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2022-01-27 — — US claimed
EP-3854788-A1 COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SK Biopharmaceuticals Co., Ltd. (KR) 2021-07-28 — — EP claimed
US-20210115001-A1 Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-04-22 — — US claimed
WO-2020060299-A1 COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 에스케이바이오팜 주식회사 2020-03-26 — — WO claimed
US-20250034101-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-01-30 — — US disclosed
US-12145914-B2 Compound having oxadiazole and pharmaceutical composition containing the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-11-19 — — US disclosed
US-20230150955-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-05-18 — — US disclosed
US-20230150955-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-05-18 — — US disclosed
US-20230150955-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-05-18 — — US disclosed
US-11603358-B2 Compound having oxadiazole and pharmaceutical composition containing the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-03-14 — — US disclosed
EP-3854788-A1 COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SK Biopharmaceuticals Co., Ltd. (KR) 2021-07-28 — — EP disclosed
US-11053208-B2 Compound having oxadiazole and pharmaceutical composition containing the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-07-06 — — US disclosed
US-11053208-B2 Compound having oxadiazole and pharmaceutical composition containing the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-07-06 — — US disclosed
US-20210115001-A1 Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-04-22 — — US disclosed
US-20210115001-A1 Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-04-22 — — US disclosed
WO-2020060299-A1 COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 에스케이바이오팜 주식회사 2020-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150955-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OTC, OXA1L, ATP6V1B2 CYP2C9 8/4885CYP1A2 35/4885MEN1 1412/4885
US-20220024886-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OTC, OXA1L, ATP6V1B2 CYP2C9 8/4885CYP1A2 35/4885MEN1 1412/4885
US-20250034101-A1 COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OTC, OXA1L, ATP6V1B2 CYP2C9 8/4885CYP1A2 35/4885MEN1 1412/4885
US-11053208-B2 Compound having oxadiazole and pharmaceutical composition containing the same OTC, OXA1L, ATP6V1B2 CYP2C9 8/4885CYP1A2 35/4885MEN1 1412/4885
US-20210115001-A1 Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same OTC, OXA1L, ATP6V1B2 CYP2C9 8/4885CYP1A2 35/4885MEN1 1412/4885
US-11603358-B2 Compound having oxadiazole and pharmaceutical composition containing the same OTC, OXA1L, ATP6V1B2 CYP2C9 8/4885CYP1A2 35/4885MEN1 1412/4885
US-12145914-B2 Compound having oxadiazole and pharmaceutical composition containing the same OTC, OXA1L, ATP6V1B2 CYP2C9 8/4885CYP1A2 35/4885MEN1 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback